George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAthelney Tst. Regulatory News (ATY)

Share Price Information for Athelney Tst. (ATY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 177.50
Bid: 165.00
Ask: 190.00
Change: 0.00 (0.00%)
Spread: 25.00 (15.152%)
Open: 177.50
High: 177.50
Low: 177.50
Prev. Close: 177.50
ATY Live PriceLast checked at -
Athelney is an Investment Trust

To provide shareholders with prospects of long term capital growth by investing in companies with either a full listing on the London Stock Exchange or a trading facility on AIM or ISDX.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Net Asset Value(s)

5 Mar 2024 14:04

RNS Number : 6796F
Athelney Trust PLC
05 March 2024
 

Athelney Trust PLC

 

Legal Entity Identifier:

213800ON67TJC7F4DL05

The unaudited net asset value of Athelney Trust was 192.7p at 29 February 2024.

Fund Manager's comment for February 2024

Recent UK data indicated that the February composite PMI rose further to 53.3, reflecting a modest expansion in an environment where costs have continued to increase due in part to higher labour costs as well as rising freight costs linked to the Red Sea crisis. In Europe, the ECB has made significant progress in reducing the February inflation rate to 2.6% after it peaked in October 2022 at 10.7% with lower natural gas prices contributing to the decline. However, with unemployment at record lows, policymakers are wary of moving too aggressively in lowering interest rates, and have indicated an increasingly clear preference to see how wages trend before making a decision to adjust interest rates. This was made clear by the US Federal Reserve member, Christopher Waller, when he said on Thursday that policymakers should delay interest rate cuts for at least another couple of months to see if the recent uptick in inflation signals a stalling of progress towards price stability, or whether it is just a bump in the road.

These cautious comments appeared to be ignored by the stock markets as the NASDAQ continued to power along, up by 6.12% for the month. The S&P500 also benefited from the positive sentiment in the equity markets, reporting an 5.17% improvement over the month as did the MSCI which was up by 4.11%. The UK markets remained in the doldrums, with the FTSE down by 0.01%, the FTSE 250 down by 1.57%, the Small Cap Index down by 0.62% and the AIM All-Share index down by 2.42%.  The Athelney portfolio declined by 5.6%, during the month and after allowing for expenses, including additional audit and related fees, the NAV reflected a decline of 5.86%.

The under-performance in February for the most part was due to a material decline in the value of our holding in Close Brothers (CBG) following an announcement by the FCA of a review of historical motor finance commission arrangements. The financial impact of this on the group is difficult to determine and when the CBG board decided to not pay any dividends on its ordinary shares for the current financial year and indicated that the reinstatement of dividends will only be reviewed once the FCA has concluded its review, we sold our entire holding. We also sold our holding in Target Healthcare and top sliced our holding in 4Imprint and the NWF Group, adding to our position in XP power, London Metric Property and introducing WISE to the portfolio. 

Wise is a high-growth, high-margin, founder-led tech business focused on reducing the cost of cross-border money movement in an extremely inefficient legacy banking network. The intermediary-heavy nature of this network creates pressure to keep fees high, as does banks' short-term profit motive to continue earning the highly profitable income stream from the cross-border transactions.

Our cash holding at month end increased to 6.2% of the portfolio.

Fact Sheet

An accompanying fact sheet which includes the information above as well as wider details on the portfolio can be found on the Fund's website www.athelneytrust.co.uk under "About" then select "Latest Monthly Fact Sheet".

 

Background Information

Dr. Emmanuel (Manny) Pohl AM

Manny is Chairman and Chief Investment Officer of E C Pohl & Co ("ECP"), an investment management company and has been a major shareholder in Athelney trust for many years.

E C Pohl & co is licensed by the Australian Financial services (license no.421704).

www.ecpohl.com

www.ecpam.com

Manny Pohl and the ECP group has AUD2.7bn (£1.5 billion) under its management including four listed investment companies, three listed in Australia and one in the UK:

· Flagship Investments (ASX code:FSI)

AUD95m https://flagshipinvestments.com.au

· Barrack St Investments (ASX code: BST)

AUD37m www.barrackst.com

· Global Masters Fund Limited (ASX code: GFL)

AUD33m www.globalmastersfund.com.au

· Athelney Trust plc (LSE code: ATY)

GBP6m www.athelneytrust.co.uk

Athelney Trust plc Investment Policy

 The investment objective of the Trust is to provide shareholders with prospects of long-term capital growth with the risks inherent in small cap investment minimised through a spread of holdings in quality small cap companies that operate in various industries and sectors. The Fund Manager also considers that it is important to maintain a progressive dividend record.

The assets of the Trust are allocated predominantly to companies with either a full listing on the London Stock Exchange or a trading facility on AIM or ISDX. The assets of the Trust have been allocated in two main ways: first, to the shares of those companies which have grown steadily over the years in terms of profits and dividends but, despite this progress, the market rating is favourable when compared to future earnings and dividends; second, to those companies whose shares are standing at a favourable level compared with the value of land, buildings or cash in the balance sheet.

Athelney Trust was founded in 1994. In 1996 it was one of the ten pioneer members of the Alternative Investment Market ("AIM"). In 2008 the shares became fully listed on the main market of the London Stock Exchange. Athelney Trust has a successful progressive dividend growth record and the dividend has grown every year since 2004. According to the Association of Investment Companies (AIC) Athelney Trust is a "Dividend Hero" being one of only a few investment companies that have increased their dividend every year for 20 years or more. See link

https://www.theaic.co.uk/income-finder/dividend-heroes

Website

www.athelneytrust.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NAVBSGDXXGGDGSU
Date   Source Headline
4th Apr 20249:21 amRNSNet Asset Value(s)
22nd Mar 20248:15 amRNSAGM Statement
5th Mar 20242:04 pmRNSNet Asset Value(s)
13th Feb 202411:58 amRNSDividend Declaration
5th Feb 202410:17 amRNSNet Asset Value(s)
3rd Jan 202411:13 amRNSNet Asset Value(s)
5th Dec 20232:45 pmRNSNet Asset Value(s)
6th Nov 20237:00 amRNSNet Asset Value(s)
20th Oct 20237:29 amRNSAuditor appointment
10th Oct 202310:54 amRNSChange of Adviser
4th Oct 20232:58 pmRNSNet Asset Value(s)
4th Sep 202311:17 amRNSNet Asset Value(s)
2nd Aug 20239:06 amRNSNet Asset Value(s)
25th Jul 202311:37 amRNSHalf-year Report
4th Jul 20238:50 amRNSNet Asset Value(s)
5th Jun 20237:28 amRNSNet Asset Value(s)
3rd May 202310:14 amRNSNet Asset Value(s)
4th Apr 202312:05 pmRNSNet Asset Value(s)
17th Mar 20231:15 pmRNSResult of AGM
2nd Mar 202312:39 pmRNSNet Asset Value(s)
13th Feb 20236:02 pmRNSAnnual Financial Report
2nd Feb 20237:00 amRNSNet Asset Value(s)
9th Jan 202310:11 amRNSNet Asset Value(s)
5th Dec 20227:51 amRNSNet Asset Value(s)
2nd Nov 20227:50 amRNSNet Asset Value(s)
4th Oct 20229:02 amRNSNet Asset Value(s)
5th Sep 20227:09 amRNSNet Asset Value(s)
2nd Aug 202211:57 amRNSNet Asset Value(s)
26th Jul 202212:44 pmRNSHalf-year Report
4th Jul 20229:13 amRNSNet Asset Value(s)
6th Jun 20229:36 amRNSNet Asset Value(s)
4th May 20227:56 amRNSNet Asset Value(s)
5th Apr 20223:10 pmRNSAGM Statement
4th Apr 20229:55 amRNSNet Asset Value(s)
2nd Mar 202211:33 amRNSNet Asset Value(s)
23rd Feb 20221:13 pmRNSAnnual Financial Report
2nd Feb 20229:05 amRNSNet Asset Value(s)
12th Jan 20225:03 pmRNSHolding(s) in Company
12th Jan 20225:00 pmRNSHolding(s) in Company
12th Jan 20225:00 pmRNSHolding(s) in Company
5th Jan 20228:14 amRNSNet Asset Value(s)
3rd Dec 202112:00 pmRNSNet Asset Value(s)
2nd Nov 20218:12 amRNSNet Asset Value(s)
4th Oct 202111:40 amRNSNet Asset Value(s)
2nd Sep 202111:44 amRNSNet Asset Value(s)
3rd Aug 20211:18 pmRNSNet Asset Value(s)
27th Jul 202111:20 amRNSHalf-year Report
2nd Jul 20218:32 amRNSNet Asset Value(s)
3rd Jun 20218:19 amRNSNet Asset Value(s)
5th May 20219:19 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.